Literature DB >> 10079472

Clinical trials referral resource. Clinical trials of MGI-114.

A Murgo, D J Cannon, G Blatner, B D Cheson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10079472

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  4 in total

1.  Irofulven induces replication-dependent CHK2 activation related to p53 status.

Authors:  Yutian Wang; Timothy Wiltshire; Jamie Senft; Eddie Reed; Weixin Wang
Journal:  Biochem Pharmacol       Date:  2006-10-27       Impact factor: 5.858

2.  Acute retinal toxicity from the novel anti-tumor agent, Irofulven.

Authors:  Robert F Melendez; Joseph M Harrison; Eric K Rowinsky; Lisa A Hammond; Thomas D Fitzsimmons
Journal:  Doc Ophthalmol       Date:  2004-05       Impact factor: 2.379

3.  Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.

Authors:  F Giles; J Cortes; G Garcia-Manero; S Kornblau; E Estey; M Kwari; A Murgo; H Kantarjian
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

4.  The pharmacological potential of mushrooms.

Authors:  Ulrike Lindequist; Timo H J Niedermeyer; Wolf-Dieter Jülich
Journal:  Evid Based Complement Alternat Med       Date:  2005-09       Impact factor: 2.629
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.